News

RXi Pharmaceuticals president and CEO Geert Cauwenbergh said: "Iovance is the leading company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology. Our agreement will allow Iovance

In 2010, the oral disease-modifying therapy (DMT) was approved by the US Food and Drug Administration (FDA) for the treatment of RMS for patients aged 18 years and

Amryt estimates there may be up to 450 additional patients who could benefit from treatment with Lojuxta across the countries covered by the extended agreement, representing an increase

The committee’s non-binding recommendation will be considered by the FDA in its review of Akcea’s New Drug Application for WAYLIVRA.  The PDUFA date for completion of the review

Armo is currently developing drugs that are designed to trigger the immune system of cancer patients to identify and kill tumors. With the acquisition, Lilly expects to strengthen

As per terms of the deal, Genentech will use Lodo Therapeutics’ genome mining and biosynthetic cluster assembly platform to discover novel molecules with therapeutic potential against multiple disease-related targets.

Focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs), Escient will initially pursue therapies for neuro-immuno-inflammatory and autoreactive

DUBs are a family of over a hundred proteases that play important roles in protein and cellular homeostasis, processes that are critical to normal cell function. Evidence suggests

The specialty pharmaceutical company had submitted a new drug application, seeking approval for Tlando as TRT for adult males with conditions caused by deficiency of endogenous testosterone (hypogonadism). Lipocine